Ultragenyx Pharmaceutical Inc
F:UP0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Ultragenyx Pharmaceutical Inc
F:UP0
|
US |
|
Controladora Vuela Compania de Aviacion SAB de CV
LSE:0I3G
|
MX |
|
Rexford Industrial Realty Inc
NYSE:REXR
|
US |
|
Conduent Inc
NASDAQ:CNDT
|
US |
|
A
|
ADTRAN Holdings Inc
SWB:QH9
|
US |
|
Evolus Inc
NASDAQ:EOLS
|
US |
|
C
|
Conagra Brands Inc
LSE:0I2P
|
US |
|
Brandywine Realty Trust
NYSE:BDN
|
US |
|
Publicis Groupe SA
OTC:PUBGY
|
FR |
|
A
|
Anika Therapeutics Inc
F:AKP
|
US |
|
N
|
NetEase Inc
BMV:NTESN
|
CN |
|
T
|
Thales SA
XBER:CSF
|
FR |
|
Moderna Inc
XETRA:0QF
|
US |
|
Beijing Enterprises Water Group Ltd
OTC:BJWTY
|
HK |
|
B
|
Budweiser Brewing Company APAC Ltd
F:4BB
|
HK |
|
V
|
Vale SA
MAD:XVALO
|
BR |
|
Daiwa House Industry Co Ltd
OTC:DWAHY
|
JP |
|
NetEase Inc
NASDAQ:NTES
|
CN |
Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical is a drug company focused on rare and often inherited diseases. It develops and sells medicines that treat conditions with few or no good treatment options, including disorders that affect the skeleton, metabolism, and the nervous system. Its business is built around finding and commercializing therapies for small patient groups that need specialized care. The company makes money mainly by selling approved medicines through the healthcare system, usually after doctors prescribe them and insurers or government programs help pay for them. It also earns income from partnerships, licensing deals, and collaboration agreements tied to the development or commercialization of certain products. Its main customers are patients treated by specialists, along with hospitals, clinics, payers, and health systems that help deliver and reimburse these therapies. What makes Ultragenyx different is its focus on rare-disease medicine, where success depends on deep scientific expertise, close work with specialist doctors, and the ability to support diagnosis and treatment of hard-to-find conditions. Instead of competing in broad primary-care markets, it targets small patient populations where the company can build value from highly specialized drugs and long development programs.
Ultragenyx Pharmaceutical is a drug company focused on rare and often inherited diseases. It develops and sells medicines that treat conditions with few or no good treatment options, including disorders that affect the skeleton, metabolism, and the nervous system. Its business is built around finding and commercializing therapies for small patient groups that need specialized care.
The company makes money mainly by selling approved medicines through the healthcare system, usually after doctors prescribe them and insurers or government programs help pay for them. It also earns income from partnerships, licensing deals, and collaboration agreements tied to the development or commercialization of certain products. Its main customers are patients treated by specialists, along with hospitals, clinics, payers, and health systems that help deliver and reimburse these therapies.
What makes Ultragenyx different is its focus on rare-disease medicine, where success depends on deep scientific expertise, close work with specialist doctors, and the ability to support diagnosis and treatment of hard-to-find conditions. Instead of competing in broad primary-care markets, it targets small patient populations where the company can build value from highly specialized drugs and long development programs.
Revenue: Ultragenyx reported first-quarter revenue of $136 million and said it remains fully confident in its 2026 revenue guidance.
Growth Drivers: Crysvita, DOJOLVI, and EVKEEZA all showed solid underlying demand, while management emphasized that the business continues to benefit from a broad global commercial footprint.
GTX-102: Management highlighted encouraging longer-term Angelman syndrome data, with 66 patients on therapy for an average of 3 years and some approaching 5 years, and said Phase III top-line data remain on track for the second half of 2026.
Launch Readiness: The company said it is manufacturing and building inventory for DTX401 and UX111 ahead of their PDUFA dates later in 2026, with launch preparation well underway.
Guidance: Ultragenyx reaffirmed 2026 revenue and expense guidance and reiterated its path to profitability in 2027.
